Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a deal ...
Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and ...
Pracodawcy mają wątpliwości, czy w przypadku zwracania pracownikom wydatków na taksówki (kiedy to pracownicy wykonują obowiązki służbowe – zarówno w podróży służbowej jak i w czasie tzw. wyjścia ...
Yes, I permit this data to be processed so that I can receive the newsletter, which sometimes includes info about other projects from the Adam Mickiewicz Institute. Co-financed by the Ministry of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback